Nervous System (e.g., Central Nervous System (cns), Etc.) Affecting Patents (Class 514/17.7)
  • Publication number: 20140323408
    Abstract: Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death.
    Type: Application
    Filed: May 7, 2014
    Publication date: October 30, 2014
    Applicant: PROTEOSYS AG
    Inventor: André SCHRATTENHOLZ
  • Patent number: 8871710
    Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. The compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 28, 2014
    Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH
    Inventors: Jens Pohl, Frank Ploeger
  • Publication number: 20140315823
    Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
    Type: Application
    Filed: May 15, 2014
    Publication date: October 23, 2014
    Applicant: Duke University
    Inventors: Daniel T. Laskowitz, Hana Dawson, Brad Kolls
  • Publication number: 20140314790
    Abstract: Methods are provided for treating dementia and or impaired cognition, as well as assays useful for identifying novel anti-dementia agents. Compounds and compositions for treating dementia and or impaired cognition are also provided.
    Type: Application
    Filed: October 2, 2012
    Publication date: October 23, 2014
    Inventors: Luciano D'Adamio, Robert Tamayev, Shuji Matsuda
  • Publication number: 20140315821
    Abstract: The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.
    Type: Application
    Filed: August 24, 2012
    Publication date: October 23, 2014
    Applicant: BIAL - PORTELA & Ca, S.A.
    Inventor: Patricio Manuel Vieira Araujo Soares Da Silva
  • Publication number: 20140315785
    Abstract: The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 23, 2014
    Inventors: Jau-Shyong Hong, Liya Qin, Guorong Li, Michelle Block, Wei Zhang, Po-See Chen, Giia-Shuen Peng
  • Publication number: 20140315822
    Abstract: The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, said polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions comprising the same. The invention is also directed to the use of said polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.
    Type: Application
    Filed: November 7, 2012
    Publication date: October 23, 2014
    Applicant: CENTRE NATIONAL DE LA RECHERCE SCIENTIFIQUE
    Inventors: Christophe Prehaud, Monique Lafon, Nicolas Wolff, Zakir Khan, Elouan Terrien, Sandrine Vitry
  • Publication number: 20140315806
    Abstract: The present invention relates to veterinary decorin compositions and methods of their production.
    Type: Application
    Filed: April 22, 2014
    Publication date: October 23, 2014
    Applicant: CATALENT PHARMA SOLUTIONS, LLC
    Inventor: Gregory T. Bleck
  • Publication number: 20140315820
    Abstract: The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance. These benefits are particularly important in the treatment of conditions that require high-dose or chronic administration of botulinum toxin. Additionally, the decreased in LD50 Unit doses of inventive formulations allows for controlled administration limits diffusion. The present invention also provides methods of treating neuromuscular diseases and pain, using low-dose botulinum toxin.
    Type: Application
    Filed: March 25, 2014
    Publication date: October 23, 2014
    Inventor: Gary E. Borodic
  • Publication number: 20140315787
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 23, 2014
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20140309172
    Abstract: The present disclosure identifies caspase-1/ICE as a therapeutic target for ?-synuclein associated diseases and disorders. Related methods and compositions are also provided.
    Type: Application
    Filed: November 4, 2011
    Publication date: October 16, 2014
    Inventors: Dagmar Ringe, Gregory A. Petsko, Quyen Hoang
  • Patent number: 8859501
    Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: October 14, 2014
    Assignee: BioArctic Neuroscience AB
    Inventors: Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
  • Publication number: 20140303080
    Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 9, 2014
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Publication number: 20140303088
    Abstract: The present invention compositions and methods of using at least a portions of an isolated and purified ?-crystallin polypeptide that includes one or more ?-pleated sheets and that prevents neurotoxicity and amyloidogenesis.
    Type: Application
    Filed: April 14, 2014
    Publication date: October 9, 2014
    Applicant: The Texas A&M University System
    Inventors: Allison Ficht, Theresa Good, Ken Carson, Sungmun Lee
  • Publication number: 20140301982
    Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 9, 2014
    Applicant: REGENESANCE B.V.
    Inventors: Frank BAAS, Kees FLUITER
  • Patent number: 8853166
    Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: October 7, 2014
    Assignee: Herantis Pharma PLC.
    Inventors: Mart Saarma, Päivi Lindholm, Merja Voutilainen, Johan Peränen, Raimo Tuominen, Mikko Airavaara, Veli-Matti Leppänen, Maria Lindahl, Jaan-Olle Andressoo
  • Publication number: 20140294877
    Abstract: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.
    Type: Application
    Filed: March 4, 2014
    Publication date: October 2, 2014
    Applicant: CUREVAC GMBH
    Inventors: Patrick BAUMHOF, Thomas SCHLAKE
  • Publication number: 20140296152
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 2, 2014
    Applicants: DUKE UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Publication number: 20140296153
    Abstract: The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the loss of the myelin sheath that insulates the nerves) is an associated or causative feature. The data provided demonstrate the utility of the compounds and compositions according to this invention to promote oligodendrogenesis and myelination or remyelination.
    Type: Application
    Filed: August 8, 2012
    Publication date: October 2, 2014
    Inventors: Sara Alves Xapeli, João José Oliveira Malva, Ricardo Augsto de Melo Reis
  • Publication number: 20140288004
    Abstract: The present invention generally relates to white matter. In particular, the present invention relates to a composition that can be used for promotion the development and/or void loss of white matter. One embodiment of the present invention relates to a composition comprising lactoferrin for use in the promotion of the development of the white matter, in the treatment or prevention of a delayed development of the white matter, and or in the treatment of prevention of a loss of white matter.
    Type: Application
    Filed: November 20, 2012
    Publication date: September 25, 2014
    Applicant: NESTEC S.A.
    Inventors: Bing Wang, Magali Faure
  • Publication number: 20140286865
    Abstract: This invention relates, e.g., to a composition suitable for administration to the central nervous system (CNS), comprising a block copolypeptide hydrogel, which comprises a biologically active material that is mixed with the hydrogel or that is attached to the polypeptide chain of the hydrogel, wherein the composition is suitable for administration to the CNS. Also disclosed are methods of making and using compositions of the invention as depots or as scaffolds for cell migration, and pharmaceutical compositions and kits for implementing methods of the invention.
    Type: Application
    Filed: February 18, 2014
    Publication date: September 25, 2014
    Applicant: The Regents of the University of California
    Inventors: Timothy J. Deming, Michael V. Sofroniew, Chu-Ya Yang, BingBing Song, Yan Ao
  • Publication number: 20140287990
    Abstract: The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to concurrently treat and/or prevent two or more conditions in a patient such as HIV, cancer, malaria and inappropriate angiogenesis.
    Type: Application
    Filed: December 2, 2013
    Publication date: September 25, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Publication number: 20140287001
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Inventor: Kunwar Shailubhai
  • Patent number: 8841260
    Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: September 23, 2014
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • Publication number: 20140274904
    Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.
    Type: Application
    Filed: May 6, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
  • Publication number: 20140274906
    Abstract: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: NoNO Inc.
    Inventors: Michael Tymianski, Rongwen Li, Jonathan David Garman
  • Publication number: 20140271668
    Abstract: Provided herein are methods of promoting parkin activity in a subject, comprising: selecting a subject with a disorder associated with decreased Parkin activity; and administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Georgetown University
    Inventor: Charbel Moussa
  • Publication number: 20140256625
    Abstract: The invention provides ultra-small peptide inhibitors that are capable of preventing amyloid formation/amyloidosis.
    Type: Application
    Filed: July 9, 2012
    Publication date: September 11, 2014
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Charlotte Hauser, Anupama Lakshmanan
  • Publication number: 20140255374
    Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.
    Type: Application
    Filed: November 6, 2013
    Publication date: September 11, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventor: Scott Eliasof
  • Patent number: 8828942
    Abstract: The present invention relates to peptides or polypeptides for producing medicaments for preventing and/or treating synucleinopathies.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: September 9, 2014
    Assignee: Affiris AG
    Inventors: Markus Mandler, Harald Weninger, Radmila Santic, Christian Lahsnig
  • Patent number: 8828949
    Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: September 9, 2014
    Assignee: Angiochem, Inc.
    Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina
  • Patent number: 8828404
    Abstract: Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: September 9, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Ester Yoles, Oleg Butovsky, Jonathan Kipnis
  • Patent number: 8828937
    Abstract: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: September 9, 2014
    Assignee: Haase Investments UG
    Inventors: Petra Seemann, Stefan Mundlos, Carsten Reissner, Georg Duda, Julia Zimmer
  • Patent number: 8828943
    Abstract: A method for alleviating and/or treating epileptic seizures comprising administering a pharmaceutical composition comprising (a) lacosamide and/or a pharmaceutically acceptable salt thereof; and (b) levetiracetam and/or a pharmaceutically acceptable salt thereof is described.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: September 9, 2014
    Assignee: UCB Pharma GmbH
    Inventor: Thomas Stöhr
  • Patent number: 8828389
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: September 9, 2014
    Assignee: Amorfix Life Sciences Ltd.
    Inventor: Neil Cashman
  • Publication number: 20140249091
    Abstract: Methods and materials are provided for the production of glycosylated peptides that exhibit high affinity and specificity for delta opioid receptors. The methods and materials of the present invention may be used for treatment of conditions involving pain, such as acute pain and nociceptic pain, neuralgia and myalgia.
    Type: Application
    Filed: October 8, 2013
    Publication date: September 4, 2014
    Applicant: BIOUSIAN BIOSYSTEMS, INC.
    Inventors: Robin Polt, Edward J. Bilsky
  • Patent number: 8822418
    Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: September 2, 2014
    Assignee: Brown University
    Inventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth McKechnie, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Patent number: 8815808
    Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: August 26, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Anders Nykjaer, Claus Munck Petersen
  • Patent number: 8815809
    Abstract: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4? is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterized by inappropriate expression or activation of cathepsin S.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: August 26, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Karolina Ersmark, Urszula Grabowska, Ellen Hewitt, Daniel Jönsson, Pia Kahnberg, Björn Klasson, Peter Lind, Stina Lundgren, Lourdes Odèn, Kevin Parkes, Daniel Wiktelius
  • Patent number: 8815810
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 26, 2014
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • Patent number: 8816046
    Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: August 26, 2014
    Assignee: The University of Colorado, a body corporate
    Inventor: K. Ulrich Bayer
  • Publication number: 20140228298
    Abstract: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.
    Type: Application
    Filed: February 4, 2014
    Publication date: August 14, 2014
    Applicant: Henry Ford Health Systems
    Inventors: John Anagli, Donald Seyfried
  • Publication number: 20140228277
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: August 14, 2014
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • Publication number: 20140228299
    Abstract: The present invention provides an agent for neurological disease, the agent comprising lipoprotein containing apolipoprotein E as the active substance thereof, in which a neuroprotective system via activation of neuroprotective molecules and/or the inactivation of neurodegeneration-inducing molecules, mediated by lipoprotein receptors, may work as a mechanism, and a prophylactic and therapeutic method for neurological diseases. The lipoproteins containing apolipoprotein E and/or neuroprotective system through, as the action mechanism, the activation of neuroprotective molecules and the inactivation of neurodegeneration-inducing molecules that are mediated by lipoprotein receptors have prophylactic and therapeutic effects of, including, inhibiting nerve cell apoptosis, on neurological disease such as various neurodegenerative diseases accompanied by nerve cell apoptosis as the essential condition.
    Type: Application
    Filed: September 19, 2012
    Publication date: August 14, 2014
    Applicants: National University Corporation Tokyo Medical and Dental University, National University Corporation Kumamoto University
    Inventor: Hideki Hayashi
  • Publication number: 20140227185
    Abstract: The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs. Thereto, the compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to glutathione-based ligands that facilitate the specific binding to and internalization by these glutathione transporters.
    Type: Application
    Filed: March 18, 2014
    Publication date: August 14, 2014
    Applicant: TO-BBB HOLDING B.V.
    Inventor: Pieter Jaap GAILLARD
  • Patent number: 8802088
    Abstract: The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: August 12, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Cinderalla C. Gerhardt, Luppo Edens
  • Patent number: 8802630
    Abstract: A novel use of a neuropeptide for treating brain injury in a subject in need thereof is provided. The present invention also provides various amenable routes of administering urocortin, that is, via injection intracerebroventricularly and intraperitoneally, and via intravenous bolus administration.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: August 12, 2014
    Assignee: Buddhist Tzu Chi Medical Foundation
    Inventors: Cheng-Yoong Pang, Mei-Jen Wang, Hock Kean Liew, Hsin-Yi Huang, Chih-Wei Hsu, Jon-Son Kou, Ting-Yi Li, Hsiao-Fen Peng, Jia-Yi Wang
  • Publication number: 20140219974
    Abstract: Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood brain barrier. Embodiments of the invention are also directed to methods of using the compositions for treating or preventing a neurological disorder, disease, or symptom in a subject in need thereof.
    Type: Application
    Filed: May 18, 2012
    Publication date: August 7, 2014
    Applicant: Children's Hospital Medical Center
    Inventor: Dao Pan
  • Patent number: 8796213
    Abstract: Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: August 5, 2014
    Assignee: Qunicy Bioscience, LLC
    Inventor: Mark Y. Underwood
  • Patent number: 8796215
    Abstract: The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C-and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: August 5, 2014
    Assignee: Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal